According to Marinus Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5. At the end of 2022 the company had a P/E ratio of -9.71.
Year | P/E ratio | Change |
---|---|---|
2022 | -9.71 | 119.8% |
2021 | -4.42 | 7.15% |
2020 | -4.12 | 90.34% |
2019 | -2.17 | -32.1% |
2018 | -3.19 | -67.95% |
2017 | -9.95 | 1348.35% |
2016 | -0.6871 | -84.89% |
2015 | -4.55 | -46.25% |
2014 | -8.46 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | -0.2783 | -94.43% | ๐บ๐ธ USA |
![]() | 2.14 | -142.83% | ๐บ๐ธ USA |
![]() | -0.0001 | -100.00% | ๐ฎ๐ช Ireland |
![]() | 41.2 | -923.37% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.